American Gene Engineer Corp (1600784) SEC Filing 10-Q Quarterly report for the period ending Monday, April 30, 2018

SEC Filings

1600784 Quarterly Reports

American Gene Engineer Corp

CIK: 1600784
Document and Entity Information - shares
6 Months Ended
Apr. 30, 2018
Jun. 11, 2018
Document And Entity Information  
Entity Central Index Key0001600784 
Document Type10-Q 
Trading SymbolAGEC 
Document Period End DateApr. 30, 2018 
Amendment Flagfalse 
Current Fiscal Year End Date--10-31 
Entity a Well-known Seasoned IssuerNo 
Entity a Voluntary FilerNo 
Entity's Reporting Status CurrentYes 
Entity Filer CategorySmaller Reporting Company 
Entity Common Stock, Shares Outstanding 100,000,000
Document Fiscal Period FocusQ2 
Document Fiscal Year Focus2018 

View differences made from one quarter to another to evaluate American Gene Engineer Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Gene Engineer Corp.


Assess how American Gene Engineer Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

American Gene Engineer Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors